Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 4/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.42 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12862879 | 0.81 | HTT (0.45) | HTTALDH1A1AKR1B1PKMMEN1 | |
| SCHEMBL5937030 | 0.80 | CHRNB4 (0.51) | CHRNB4CHRNA3HTTTDP1ALDH1A1 | |
| SCHEMBL5937089 | 0.80 | CHRNB4 (0.51) | CHRNB4CHRNA3HTTALDH1A1MEN1 | |
| SCHEMBL1168091 | 0.79 | ADRA2A (0.42) | CHRNB4CHRNA3ALDH1A1TSHRAKR1B1 | |
| SCHEMBL10843781 | 0.78 | CHRNB4 (0.47) | CHRNB4CHRNA3TDP1ALDH1A1TSHR | |
| SCHEMBL14468282 | 0.77 | KMT2A (0.47) | HTTALDH1A1AKR1B1PKMMEN1 | |
| SCHEMBL9571155 | 0.77 | CHRNB4 (0.41) | CHRNB4CHRNA3HTTTDP1ALDH1A1 | |
| SCHEMBL12862897 | 0.76 | LOXL2 (0.41) | CHRNB4CHRNA3TDP1ALDH1A1TSHR | |
| SCHEMBL12862887 | 0.76 | PNMT (0.45) | CHRNB4CHRNA3ALDH1A1TSHRAKR1B1 | |
| SCHEMBL1169041 | 0.76 | CYP1A2 (0.43) | CHRNB4CHRNA3HTTTDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773835-B1 | PYRIDO-PYRIDO-PYRIMIDINE DERIVATIVES, PREPARATION THEREOF, THERAPEUTIC USE THEREOF FOR TREATING CANCER | SANOFI SA (FR) | 2014-09-24 | — | — | EP | disclosed |
| US-7893259-B2 | Pyrido-pyrimidine derivatives, preparation thereof, and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2011-02-22 | — | — | US | disclosed |
| US-20090233923-A1 | PYRIDO-PYRIMIDINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-09-17 | — | — | US | disclosed |
| US-7544682-B2 | Pyrido-pyrimidine derivatives, preparation thereof, and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2009-06-09 | — | — | US | disclosed |
| US-20070167469-A1 | Pyrido-pyrimidine derivatives, preparation thereof, and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167469-A1 | Pyrido-pyrimidine derivatives, preparation thereof, and therapeutic use thereof | DPYD, PNPO, TYMP | CHRNB4 3274/4885CHRNA3 2171/4885HTT 4426/4885 |
| US-20090233923-A1 | PYRIDO-PYRIMIDINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | DPYD, PNPO, TYMP | CHRNB4 3377/4885CHRNA3 2161/4885HTT 4258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.